Haemonetics Corporation 10-Q Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended July 2, 2005 (First Quarter of Fiscal Year 2006)
Business Overview: The company designs, manufactures, and markets automated systems for the collection, processing, and surgical salvage of donor and patient blood, along with single-use disposables and data management software. Operations are conducted globally, with approximately 63% of revenue generated outside the United States.
Key Financial Metrics
| Metric (in thousands) | Q1 FY2006 | Q1 FY2005 |
|---|---|---|
| Net Revenues | $103,173 | $94,602 |
| Gross Profit | $54,524 | $47,100 |
| Gross Margin | 52.8% | 49.8% |
| Operating Income | $18,495 | $14,962 |
| Operating Margin | 17.9% | 15.8% |
| Net Income | $12,884 | $9,820 |
| Diluted EPS | $0.47 | $0.38 |
| Cash and Cash Equivalents | $198,067 | $66,656 |
| Working Capital | $275,722 | $255,689 |
| Total Debt (Current + Long-term) | $45,359 | $45,843 |
| Net Cash Position | $152,708 | $20,813 |
Note: Net Cash Position is defined by the company as cash and cash equivalents less total debt.
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 9.1% year-over-year. This was driven by a 9.2% increase in disposable revenue across all product lines and a 33.5% increase in miscellaneous and service revenue. Equipment revenue declined 8.4% due to a lack of large one-time sales compared to the prior year.
- Profitability: Gross profit increased 15.8%, aided by favorable foreign exchange rates (5.5% impact), improved manufacturing efficiencies, and reduced inventory provisions. Operating income rose 23.6%.
- Net Income: Net income increased 31.2% to $12.9 million. The effective tax rate was 36.0%, compared to 32.0% in the prior year, which included a non-recurring tax benefit.
- Cash Flow: Net cash provided by operating activities increased to $11.8 million (from $9.5 million). Net cash used in investing activities improved significantly to a net outflow of $4.6 million (from $24.3 million outflow) due to the absence of short-term investment purchases that occurred in the prior year.
- Foreign Exchange: Favorable currency fluctuations contributed 2.8% to revenue growth and 5.5% to gross profit growth.
Guidance, Outlook, Risks, and Unusual Items
- Product Delays and Recalls: The company voluntarily recalled 33 CardioPAT devices due to a potential valve issue on the disposable, delaying the full market release. Corrective actions are expected to cost approximately $0.1 million. Additionally, the launch of the CritScan device (non-invasive hematocrit testing) has been delayed as it is not meeting quality standards in initial trials.
- Legal Proceedings: On May 20, 2005, an arbitration panel awarded Haemonetics $27.8 million in damages plus legal costs against Baxter International, Inc. regarding supply contract obligations. The company will record this amount only when collection is certain and probable.
- Accounting Changes: The company anticipates adopting SFAS No. 123R (Share-Based Payments) in the first quarter of fiscal 2007, which will require fair value accounting for stock options and is expected to have a significant impact on reported earnings.
- Market Risks: Significant exposure to foreign exchange rates (Japanese Yen and Euro). The company uses forward contracts to hedge anticipated cash flows. Interest rate risk is minimal as long-term debt is fixed-rate.
Investor Verification Checklist
- Arbitration Collection: Verify the status of the $27.8 million Baxter arbitration award and the likelihood of collection to determine if it will be recognized in upcoming quarters.
- Product Launch Timeline: Monitor the resolution of the CardioPAT valve issue and the quality testing of the CritScan device to assess potential revenue impacts from delayed launches.
- Foreign Exchange Sensitivity: Review the impact of currency fluctuations on future margins, as 63% of revenue is international and the company relies on hedging strategies.
- Stock-Based Compensation Impact: Assess the projected impact of the upcoming adoption of SFAS No. 123R on future net income and EPS.
- Inventory Levels: Note the increase in inventory ($56.0 million) and accounts receivable ($83.6 million) relative to sales growth to ensure working capital efficiency remains stable.